Atossa Therapeutics
ATOS
67 hedge funds and large institutions have $13M invested in Atossa Therapeutics in 2025 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 20 increasing their positions, 9 reducing their positions, and 10 closing their positions.
172% more call options, than puts
Call options by funds: $166K | Put options by funds: $61K
122% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 9
40% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 10
2% more funds holding
Funds holding: 66 → 67 (+1)
0.13% more ownership
Funds ownership: 1% → 1.13% (+0.13%)
23% less capital invested
Capital invested by funds: $16.8M → $13M (-$3.84M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$884K |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$708K |
| 3 |
Renaissance Technologies
New York
|
+$433K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$324K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$306K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$359K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$269K |
| 3 |
Squarepoint
New York
|
-$220K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$73.8K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$55.5K |
ATOS Hedge Fund Activity: Q4 2025 in Review
67 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q4 2025, worth a combined $13M — down 23% from $16.8M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ATOS positions and 10 closed out — a net gain of 4 holders — while 20 added to existing stakes and 9 trimmed.
The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $884K. The largest seller was Millennium Management, cutting an estimated $359K.
- 67 institutional investors held Atossa Therapeutics (ATOS) as of Q4 2025, up from 66 in Q3 2025.
- Funds reported $13M of Atossa Therapeutics stock for Q4 2025, down 23% quarter-over-quarter.
- 14 funds opened new Atossa Therapeutics positions in Q4 2025 and 10 closed out, a net change of +4 holders.
- The largest Atossa Therapeutics buyer in Q4 2025 was Jacobs Levy Equity Management, an estimated $884K added.
- The largest Atossa Therapeutics seller in Q4 2025 was Millennium Management, an estimated $359K sold.
Based on aggregated 13F filings for Q4 2025.